Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
38 results
D2.394 - Mycoplasma-Induced Drug Hypersensitivity: Rare Complication or Coincidence?
D2.395 - Erdosteine-induced multifocal fied drug eruption: a case series of five patients
D2.399 - Successful Deferasirox Desensitization in a Patient with Delayed-Type Hypersensitivity
D2.402 - Latex Sensitization as a Risk Factor for Perioperative Hypersensitivity Reactions in Asthmatic Children
D2.403 - When a Topical Drug Goes Systemic: A Case of Dual Hypersensitivity to Diltiazem
D2.405 - UnDRESSing AGEP and Revealing Erythema Multiforme
D2.406 - Severe DRESS in an oncohematological patient: diagnostic and therapeutic challenges
D2.393 - Aspirin hypersensitivity and desensitization-Sense and sensibility
D2.396 - Successful Desensitization in a Patient with a Delayed Type Hypersensitivity Reaction to Ethambutol
D2.397 - Immediate and Delayed Hypersensitivity Reactions to Multiple Thyroid Hormone Preparations: A Challenging Case
D2.398 - Ibuprofen Challenge or Desensitisation in Myo-Pericardial Disease: A Case Series
D2.400 - Vitamin Hypersensitivity in the Era of Intravenous ‘Cocktails’: Diagnostic Pitfalls and Clinical Consequences
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download